Medimscience
Latest round
- Series A
Last raised
- Apr 2026
Total raised
- $22M
Investors
- 4
About Medimscience
, dba Medimscience, is a biotechnology company that engages in the research and development of macromolecular drug. Based on new targets on macrophages, the company develops first-in-class that promote tumor immune microenvironment reprogramming. The company mainly provides tumor immunotherapy drugs, but also provides antibody drug research and development technical services, such as protein customization services, monoclonal antibody drug screening, etc. The company generates revenue from the sales of medicine for macrophages in the tumor immune microenvironment.
Who invested in Medimscience
4 investors across 2 rounds
See all investors in Medimscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Medimscience
Who invested in Medimscience?
Medimscience has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Medimscience raised?
Medimscience has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Medimscience last raise money?
Medimscience's most recent round on record is a Series A, in Apr 2026.
What does Medimscience do?
, dba Medimscience, is a biotechnology company that engages in the research and development of macromolecular drug.
Where is Medimscience headquartered?
Medimscience is headquartered in Hangzhou, China.
Which VCs invest in companies like Medimscience?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Medimscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Medimscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.